ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2018

Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.

Umberto Restelli et al.PubMed ↗Publisher ↗

No numbers read from the abstract.